RT Journal Article
SR Electronic
T1 Passive Microwave Radiometry (MWR) for diagnostics of COVID-19 lung complications in Kyrgyzstan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.29.20202598
DO 10.1101/2020.09.29.20202598
A1 Osmonov, Batyr
A1 Ovchinnikov, Lev
A1 Galazis, Christopher
A1 Emilov, Berik
A1 Karaibragimov, Mustafa
A1 Seitov, Meder
A1 Vesnin, Sergey
A1 Mustafin, Chingiz
A1 Kasymbekov, Turat
A1 Goryanin, Igor
YR 2020
UL http://medrxiv.org/content/early/2020/10/19/2020.09.29.20202598.abstract
AB It becomes clear that the COVID-19 virus is spreading globally due to limited access to diagnostics tests and equipment. Now, most of the diagnostics has been focused on RT-PCR, chest CT manifestations of COVID-19. However, there are problems with CT due to infection control, lack of CT availability in LMIC (Low Middle Income Countries) and sensitivity of RT-PCR. Passive microwave radiometry (MWR) is a cheap, non-radioactive and portable technology. It has already been used for diagnostics of cancer, and other diseases. We have tested if MWR could be used for early diagnostics of pulmonary COVID-19 complications. This was a randomized controlled trial to evaluate MWR in patients with COVID-19 pneumonia in hospitals, and in healthy individuals. We have measured skin and internal temperature at 30 points on both lungs. Pneumonia and lung damage were diagnosed by CT scan and doctor diagnosis (pn+/pn-). COVID-19 was determined by RT-PCR tests (covid+/covid-). The best MWR results were obtained between pn-/covid- and pn+/covid+ groups with sensitivity 92% and specificity 75%. The study suggests that the MWR is a safe method for diagnostics of pneumonia in COVID-19 patients. Since MWR is an inexpensive, it will ease the financial burden for both patients and the countries.Clinical Trial Number NCT04568525Study design Randomized controlled clinical trialsCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04568525Funding StatementSFC-GCRF COVID-19 C-10256327Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Kyrgyz Republic Review Board 01-2/141 27 May 2020All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe xls file with blinded clinical data is attached in supplementary materials.